Payment overview · 2025
General Payments
$390.44
22 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Allen Loden, MD
Allopathic & Osteopathic Physicians|Family Medicine · WACO, TX · NPI 1922089382
Verified facts
What the public records show
CMS Open Payments records show Michael Allen Loden, MD received $390.44 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.71 | 27.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.20 | 18.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.48 | 16.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.65 | 16.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.64 | 8.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.57 | 4.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.18 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.60 | 2.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $6.41 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $390.44 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $94.45 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.45 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $70.20 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.65 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.65 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $34.64 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $34.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.60 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $6.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
219 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 821 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 776 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 552 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 129 |
| Gabapentin | Gabapentin | 478 | 107 |
| Metformin Hcl Er | Metformin Hcl | 471 | 113 |
| Losartan Potassium | Losartan Potassium | 445 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 68 |
| Tramadol Hcl | Tramadol Hcl | 315 | 66 |
| Alendronate Sodium | Alendronate Sodium | 314 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 278 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 264 | 58 |
| Potassium Chloride | Potassium Chloride | 262 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 220 | 37 |
| Ozempic | Semaglutide | 219 | 40 |
| Alprazolam | Alprazolam | 215 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 44 |
| Trazodone Hcl | Trazodone Hcl | 194 | 33 |
| Nifedipine Er | Nifedipine | 179 | 36 |
| Carvedilol | Carvedilol | 168 | 39 |
| Ezetimibe | Ezetimibe | 162 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 42 |
| Montelukast Sodium | Montelukast Sodium | 159 | 38 |
| Sertraline Hcl | Sertraline Hcl | 159 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 158 | 35 |
| Pregabalin | Pregabalin | 158 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 153 | 32 |
| Lisinopril | Lisinopril | 151 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 43 |
| Atenolol | Atenolol | 134 | 29 |
| Furosemide | Furosemide | 133 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 30 |
| Metformin Hcl | Metformin Hcl | 126 | 28 |
| Allopurinol | Allopurinol | 124 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 25 |
| Omeprazole | Omeprazole | 122 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 118 | 22 |
| Ramipril | Ramipril | 115 | 23 |
| Jardiance | Empagliflozin | 113 | 18 |
| Memantine Hcl | Memantine Hcl | 103 | 20 |
| Eliquis | Apixaban | 101 | 22 |
| Synthroid | Levothyroxine Sodium | 97 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 14 |
| Bupropion Xl | Bupropion Hcl | 95 | 18 |
| Simvastatin | Simvastatin | 92 | 24 |
| Solifenacin Succinate | Solifenacin Succinate | 90 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 23 |
| Glimepiride | Glimepiride | 87 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 85 | 20 |
| Prednisone | Prednisone | 78 | 55 |
| Raloxifene Hcl | Raloxifene Hcl | 77 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 19 |
| Meloxicam | Meloxicam | 72 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 71 | 12 |
| Clonazepam | Clonazepam | 68 | 12 |
| Spironolactone | Spironolactone | 66 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | suppressed |
| Celecoxib | Celecoxib | 64 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 46 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 11 |
| Estradiol | Estradiol | 56 | 17 |
| Cephalexin | Cephalexin | 54 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 34 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 14 |
| Primidone | Primidone | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | 11 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 25 |
| Azithromycin | Azithromycin | 36 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 20 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Minocycline Hcl | Minocycline Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Wegovy | Semaglutide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Klor-Con | Potassium Chloride | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | 11 |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $390.44 · 22 records | ABBVIE INC. | ABRYSVO, COMIRNATY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ELIQUIS, NEXPLANON, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error